All In MedTech

FDA Clearance Tracker · P910056-S036

enVista One Piece Hydrophobic Acrylic Intraocular Lens

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 2, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 2, 2019

Approved

Time to decision

90 days

Received Apr 3, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P910056-S036
Device name
enVista One Piece Hydrophobic Acrylic Intraocular Lens
Applicant location
Irvine, CA
Received
Apr 3, 2019
Decided
Jul 2, 2019
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P910056

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code HQL

FDA's approval statement

As written in FDA's record.

Approval of the enVista® One Piece Hydrophobic Acrylic IOL, Model MX60ET, which includes a modification to the intraocular lens (IOL) material formulation of the approved parent lens, enVista® Model MX60T.

Source documents

Other decisions for Bausch & Lomb, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.